Rucaparib Maintenance Therapy in Advanced Cervical Cancer

NCT ID: NCT03795272

Last Updated: 2019-11-01

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-01
• Study Completion Date: 2019-10-10

Brief Summary

To evaluate the efficacy of PARP inhibitor, rucaparib as maintenance therapy for locally advanced cervical cancer

Detailed Description

The use of concomitant cisplatin-based chemo-radiation for cervical cancer has improved survival of locally advanced cervical cancer patients and has become the standard of care. A meta-analysis revealed that the addition of concurrent chemotherapy to radiation increased the 5-year overall survival rate by 6% (HR 0.81: 60 vs 66%), and 5-year disease-free survival rate by 8%, though there is still considerable need for improvement as most patients who relapse are incurable. The unmet need is particularly higher in patients that are at high risk of recurrence. The main negative prognostic factors are higher FIGO stage as well as the presence of positive lymph nodes. Current studies are evaluating role of adjuvant chemotherapy following chemo-radiation in locally advanced disease and will possibly improve survival by reducing risk of distant metastases, however at the cost of excessive toxicity.

PARP inhibitors have shown considerable clinical benefit especially in platinum-sensitive relapsed ovarian cancer. Several PARP inhibitors have been evaluated in other gynaecological malignancies and three PARP inhibitors (olaparib, rucaparib & niraparib) are approved by European Medicines Agency and Food & Drug Administration for treatment or as maintenance therapy in ovarian cancer. Human papillomavirus causes oxidative stress that may result in DNA single-strand breaks. In cervical cancer PARP-1 expression/activity may be up-regulated in response to the ongoing oxidative stress (HPV and inflammation), and this may promote progression. This may create a vicious circle of inflammation, PARP activation, NAD+ consumption, adenosine triphosphate consumption, necrosis, and inflammation. PARPi may limit the role of PARP-1 in promoting inflammation and oxidative stress. There is theoretical plausibility that PARPi may have a role in the treatment of cervical carcinoma.

This phase II randomized placebo-controlled double-blind study will evaluate the efficacy and safety of rucaparib as adjuvant treatment for patients with locally advanced cervical cancer who are responding to chemo-radiation. This investigator-initiated study will be performed within the GCIG/ENGOT collaboration

Conditions

Cervical Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Rucaparib

Patients will be treated with active oral drug, Rucaparib twice daily for 24 months

Group Type: EXPERIMENTAL

Rucaparib

Intervention Type: DRUG

2:1 randomization to receive rucaparib/placebo twice daily for 24 month

Placebo

Patients will be treated with oral placebo twice daily for 24 months

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

placebo

Interventions

Rucaparib

2:1 randomization to receive rucaparib/placebo twice daily for 24 month

Intervention Type: DRUG

Placebo

placebo

Intervention Type: DRUG

Other Intervention Names

active maintenance; matched placebo maintenance

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed squamous cell, adenocarcinoma or adenosquamous carcinoma of the cervix.

2. Patient must have completed definitive chemoradiation and is evaluated to be in complete remission 10-12 week's post definitive treatment.

3. Initial FIGO stage IIB with positive nodes (histological verification or verified by MRI/PET-CT), FIGO stages IIIA, IIIB, IVA; or any stage with para-aortic metastases (including IB and IIA with positive aortic nodes).

4. Toxicities resulting from definitive treatment must resolve to grade ≤1 prior to randomization.

5. Patient must consent that archival tumour tissue can be collected at the time of screening and used for translational studies.

6. Patient must consent to collection of whole blood and blood plasma during the study period. These samples will be stored and later used for translational studies.

7. Patient agrees to undergo all analysis; radiological examinations according to protocol.

8. The patient agrees to complete PROs (QoL questionnaire) during study treatment.

9. Patients must give informed consent.

10. Patients must be at least 18 years of age.

11. ECOG performance status 0-1

12. Serum albumin >30g/l.

13. Adequate organ function

• Absolute neutrophil count (ANC) ≥1,500/mcL
• Platelets >100,000/mcL
• Haemoglobin ≥ 9g/dl (no blood transfusions for 4 weeks prior entering the trial.)
• Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥50mL/min using Cockcroft-Gault formula.
• Total bilirubin ≤1.5x ULN.
• Alanine aminotransferase (ALT) ≤2.5x ULN

14. Life expectancy of at least 12 weeks.

15. Women of childbearing potential must use highly effective methods of birth control for the duration of study participation and for 6 months afterwards.

16. All patients: Patients should not donate blood or blood components while participating in this study and through 90 days after receipt of the final dose of IMP. -

2. Concurrent cancer therapies or cancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, biologic or hormonal therapy) within last 4 weeks.

3. Concurrent treatment with an investigational agent or participation in another clinical trial.

4. Previous malignant disease: patients are not eligible for the study if actively being treated of invasive cancer. Patients with previous malignant disease who are relapse-free and treatment-free for more than three years may enter this study. Patients with previous history of in-situ carcinoma of cervix, or non-invasive basal cell and squamous cell skin carcinoma can enter this trial.

5. Active infections or other serious underlying significant medical illness, abnormal laboratory finding or psychiatric illness/social situation that would, in the investigator's judgment, make the patient inappropriate for this study. Known active or chronic hepatitis C and/or B infection. Has known history of tuberculosis.

6. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.

7. Any evidence of distant metastases.

8. Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months prior to randomization, congestive heart failure >NYHA II (New York Heart Association), severe peripheral vascular disease, clinically significant pericardial effusion.

9. Pregnancy or breastfeeding. Patients with preserved reproductive capacity, unwilling to use a medically acceptable method of contraception for the duration of the trial and for 6 months afterwards.

10. Known hypersensitivity to the trial drugs, or to their excipients.

11. Persons who have been committed to an institution by official or judicial order

12. Patients with dependency on the sponsor, investigator or study site -

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Institute of Cancer Research, United Kingdom

OTHER

Sponsor Role: collaborator

Central and Eastern European Oncology Group

OTHER

Sponsor Role: collaborator

North Eastern German Society of Gynaecological Oncology

OTHER

Sponsor Role: collaborator

Belgian Gynaecological Oncology Group

OTHER

Sponsor Role: collaborator

Princess Margaret Hospital, Canada

OTHER

Sponsor Role: collaborator

PGOG (Polish Gynaecologic Oncology Group)

UNKNOWN

Sponsor Role: collaborator

GSO Global Clinical Research BV

OTHER

Sponsor Role: collaborator

GCP-enhederne

UNKNOWN

Sponsor Role: collaborator

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Rigshospitalet

Copenhagen, Region Sjælland, Denmark

Rigshospitalet

København Ø, Region Sjælland, Denmark

Countries

Denmark

Other Identifiers

ENGOT-Cx7-NSGO/MaRuC

Identifier Type: -

Identifier Source: org_study_id